-
公开(公告)号:EP3082872B1
公开(公告)日:2020-12-09
申请号:EP14821453.9
申请日:2014-12-16
申请人: Genentech, Inc. , Medimmune Limited
发明人: FLYGARE, John , GUNZNER-TOSTE, Janet , PILLOW, Thomas , SAFINA, Brian , VERMA, Vishal , WEI, Binqing , ZHAO, Guiling , STABEN, Leanna , HOWARD, Philip, Wilson , MASTERSON, Luke
IPC分类号: A61K47/68 , A61K31/5517 , A61P35/00 , A61P35/02
-
公开(公告)号:EP2968596A2
公开(公告)日:2016-01-20
申请号:EP14761432.5
申请日:2014-03-13
申请人: MEDIMMUNE LIMITED , Genentech, Inc.
IPC分类号: A61K47/48 , A61K31/5517 , C07D487/04
CPC分类号: A61K47/6869 , A61K31/5517 , A61K47/6803 , A61K47/6851 , A61K47/6855 , A61K47/6889 , A61P35/00 , C07D487/04 , C07D487/16 , C07D519/00
摘要: Conjugate compounds of formula (A): wherein: R2 is where R36a and R36b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester or, when one of R36a and R36b is H, the other is selected from nitrile and a C1-4 alkyl ester; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, NO2, Me3Sn and halo; R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, NO2, Me3Sn and halo; Y is selected from formulae A1, A2, A3, A4, A5 and A6: L is a linker connected to a cell binding agent; CBA is the cell binding agent; n is an integer selected in the range of 0 to 48; RA4 is a C1-6 alkylene group; either (a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl; or (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is OSOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; R and R′ are each independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; wherein R16, R17, R19, R20, R21 and R22 are as defined for R6, R7, R9, R10, R11 and R2 respectively; wherein Z is CH or N; wherein T and T′ are independently selected from a single bond or a C1-9 alkylene, which chain may be interrupted by one or more heteroatoms e.g. O, S, N(H), NMe, provided that the number of atoms in the shortest chain of atoms between X and X′ is 3 to 12 atoms; and X and X′ are independently selected from O, S and N(H).
摘要翻译: 式(A)的偶联化合物:其中:R 2是,其中:R 36a和R 36b独立地选自H,F,C 1-4饱和烷基,C 2-3烯基,其中烷基和烯基任选被 选自C 1-4烷基酰胺基和C 1-4烷基酯的基团; 或者当R 36a和R 36b中的一个是H时,另一个选自腈和C 1-4烷基酯; R 6和R 9独立地选自H,R,OH,OR,SH,SR,NH 2,NHR,NRR',NO 2,Me 3 Sn和卤素; R 7独立地选自H,R,OH,OR,SH,SR,NH 2,NHR,NRR',NO 2,Me 3 Sn和卤素; Y选自式A1,A2,A3,A4,A5和A6:L是与细胞结合剂连接的接头; CBA是细胞结合剂; n是在0至48范围内选择的整数; R A4是C 1-6亚烷基; (a)R 10为H,且R 11为OH,OR A,其中R A为C 1-4烷基; 或(b)R 10和R 11在它们所键合的氮原子和碳原子之间形成氮 - 碳双键; 或(c)R 10为H且R 11为OSO zM,其中z为2或3且M为单价药学上可接受的阳离子; R和R'各自独立地选自任选取代的C 1-12烷基,C 3-20杂环基和C 5-20芳基,并且任选地与基团NRR',R和R'一起与氮原子一起形成 它们连接形成任选取代的4-,5-,6-或7-元杂环; 其中R 16,R 17,R 19,R 20,R 21和R 22分别与R 6,R 7,R 9,R 10,R 11和R 2的定义相同; 其中Z是CH或N; 其中T和T'独立地选自单键或C 1-9亚烷基,该链可被一个或多个杂原子例如 O,S,N(H),NMe,条件是在X和X'之间的最短原子链中的原子数是3至12个原子; X和X'独立地选自O,S和N(H)。
-
公开(公告)号:EP2968596B1
公开(公告)日:2019-03-06
申请号:EP14761432.5
申请日:2014-03-13
申请人: MEDIMMUNE LIMITED , Genentech, Inc.
IPC分类号: A61K47/68 , C07D487/04 , C07D487/16 , C07D519/00 , A61K31/5517 , A61P35/00
-
公开(公告)号:EP3082872A1
公开(公告)日:2016-10-26
申请号:EP14821453.9
申请日:2014-12-16
申请人: Genentech, Inc. , Medimmune Limited
发明人: FLYGARE, John , GUNZNER-TOSTE, Janet , PILLOW, Thomas , SAFINA, Brian , VERMA, Vishal , WEI, Binqing , ZHAO, Guiling , STABEN, Leanna , HOWARD, Philip, Wilson , MASTERSON, Luke
CPC分类号: A61K47/48569 , A61K31/5517 , A61K47/6803 , A61K47/6851 , A61K47/6867 , A61K47/6869 , A61K47/6889 , C07K16/2851 , C07K16/30 , C07K16/3061 , C07K16/3069 , C07K16/3092 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/56
摘要: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.
摘要翻译: 本发明涉及拟肽连接体和其抗体药物缀合物,含有它们的药物组合物,以及它们在预防癌症治疗的疗法中的用途。
-
公开(公告)号:EP3931199A1
公开(公告)日:2022-01-05
申请号:EP20708054.0
申请日:2020-02-25
申请人: MedImmune Limited
IPC分类号: C07D519/00
-
公开(公告)号:EP2753178B1
公开(公告)日:2017-12-06
申请号:EP12840422.5
申请日:2012-10-12
IPC分类号: A01N43/62 , C07D487/04 , C07D519/00
CPC分类号: C07K16/2875 , A61K31/5517 , A61K47/48384 , A61K47/48561 , A61K47/6803 , A61K47/6849 , C07D487/04 , C07D519/00 , Y02A50/385 , Y02A50/414 , Y02A50/423
摘要: A conjugate or drug linker comprising the formula I, and a glucuronic acid residue
-
-
公开(公告)号:EP3054990B1
公开(公告)日:2019-03-27
申请号:EP14793027.5
申请日:2014-10-10
申请人: Medimmune Limited
IPC分类号: A61K47/68 , A61P35/00 , C07D487/04 , C07D519/00
-
公开(公告)号:EP4176904A1
公开(公告)日:2023-05-10
申请号:EP22189090.8
申请日:2020-03-23
申请人: MedImmune Limited
发明人: HOWARD, Philip, Wilson , DICKINSON, Niall , CAILLEAU, Thais , MASTERSON, Luke , GOUNDRY, William
IPC分类号: A61K47/68 , C07D491/22
摘要: A conjugate comprising the following topoisomerase inhibitor derivative (A*):
with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.-
公开(公告)号:EP4039280A1
公开(公告)日:2022-08-10
申请号:EP21213472.0
申请日:2011-04-15
申请人: Seagen Inc. , Medimmune Limited
摘要: Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs.
-
-
-
-
-
-
-
-
-